



## CORRECTION

# Correction to: Inhibition of p53 and/or AKT as a new therapeutic approach specifically targeting ALT cancers

Yuanlong Ge<sup>1,2</sup>, Shu Wu<sup>1,2</sup>, Zepeng Zhang<sup>1,2</sup>, Xiaocui Li<sup>1,2</sup>, Feng Li<sup>1</sup>, Siyu Yan<sup>1</sup>, Haiying Liu<sup>1,2</sup>, Junjiu Huang<sup>1</sup>, Yong Zhao<sup>1,2</sup>✉

<sup>1</sup> MOE Key Laboratory of Gene Function and Regulation, State Key Laboratory of Biocontrol, School of Life Sciences, Sun Yat-sen University, Guangzhou 510006, China

<sup>2</sup> Collaborative Innovation Center of High Performance Computing, National University of Defense Technology, Changsha 410073, China

✉ Correspondence: zhaoy82@mail.sysu.edu.cn (Y. Zhao)

**CORRECTION TO: PROTEIN CELL [HTTPS://DOI.ORG/10.1007/S13238-019-0634-Z](https://doi.org/10.1007/s13238-019-0634-z)**

In the original publication the labels in Fig. 4C and 4D are incorrectly published. The correct labels for Fig. 4C and 4D is provided in this correction.


### OPEN ACCESS

This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<http://creativecommons.org/licenses/by/4.0/>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

---

Yuanlong Ge and Shu Wu have contributed equally to this work.

The original article can be found online at <https://doi.org/10.1007/s13238-019-0634-z>.



**Figure 4. AKT is phosphorylated in p53-dependent manner in ALT cells.** (A) Western blot determination of total and phosphorylated AKT (S473) in p53-positive (VA13, U2OS) and p53-defective (SAOS2, SKLU-1) ALT cells. (B) Knockdown of p53 in U2OS or moderate expression of p53 in SAOS2 induces down or up-regulation of p-AKT, respectively. (C) Knockdown of ATM or ATR by siRNA decreases abundance of p53, phosphorylated p53 and p-AKT. (D) Quantitative-PCR determination of the level of ATR or ATM in U2OS cells transfected with siRNA to ATR or ATM, respectively. Scramble siRNA (Si-Ctl) was used as control. Data represent the mean±SEM, n=3-4. (E) ATM (KU60019) or ATR (VE-821) inhibitor decreases abundance of p-AKT in U2OS cells. U2OS cells were treated with indicated concentration of KU60019 or VE-821 for 24 h. (F) The expression of wt-p53, but not mutant p53 (p53-s269e) defective of transcription activity, increases the level of p-AKT. (G) PFTα, an inhibitor of p53 transcription activity, suppresses the phosphorylation of AKT. U2OS cells were treated with indicated concentration of PFTα for 24 h.